Presentation Will Provide Overview of Ongoing Clinical Trial of Salarius’ Lead Drug Candidate, Seclidemstat, in Ewing Sarcoma HOUSTON , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer,

HOUSTON , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its corporate and financial results for the quarter ended September 30, 2019.

Initial Purchase of $1 Million of Salarius Shares Completed, Aspire Capital to Purchase Additional Salarius Common Stock over a 30-Month Span Extending into 2022 HOUSTON , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting

HOUSTON , Oct. 14, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its participation at two upcoming investor conferences. Management will provide an overview of Salarius’ business

Salarius Targeting Key Safety and Efficacy Data Milestones in 2020   HOUSTON , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.  (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial Sloan Kettering Cancer Center

Fourth Level Dosing Cohorts Now Proceeding Following Safety Review Committee Clearance   HOUSTON , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that the Safety Review

Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer HOUSTON , Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the

Salarius’ lead program, Seclidemstat, is in a Phase 1 clinical trial for Ewing sarcoma, a rare and devastating pediatric bone and soft-tissue cancer; Early cohort data expected in 2020 HOUSTON , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.

Comprehensive pre-clinical study will test first-in-class investigational therapy Seclidemstat PHOENIX and HOUSTON , Aug. 26, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative

HOUSTON , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that its chief executive officer, David Arthur , issued an open letter to Salarius’ stockholders following the